OE Biomedical Completes Series A and A+ Financing to Accelerate Multi-Omics Platform Development and Molecular Diagnostic Product Innovation

Recently,Shanghai Oebiotech Co., Ltd. (hereinafter referred to as“oebiotech”)Announced as the successor toAfter securing tens of millions of yuan in Series A financing in August 2021, the company subsequently closed a Series A+ round of nearly RMB 100 million, winning investor favor upon its debut in the primary market.

It is understood that the Series A financing round of oebiotech was led by Dongzheng Capital, A+This round of financing was led by Sinopharm Capital, with Orient Securities Capital participating as a follow-on investor.Dingshi HuizeCapital participation in co-investment. The proceeds from this round of financing will be primarily used to accelerate the research and development (R&D) of molecular diagnostic products, expedite the regulatory registration and filing processes for pipeline products, enhance capabilities in multi-omics integrated analysis, and advance R&D innovation and database construction in spatial multi-omics technologies, thereby further consolidating and strengthening the company’s leading advantage in multi-omics and spatial multi-omics technologies. This round of financing was supported by MedRoad Capital.

Oebiotech, founded in 2009, is a high-tech enterprise dedicated to multi-omics testing services and the development of molecular diagnostic products. Over more than a decade of development, the company has established a comprehensive multi-omics experimental testing and big data analytics platform covering nucleic acids, proteins, and metabolites. Oebiotech provides multi-layered multi-omics testing services and solutions to pharmaceutical R&D companies, food and cosmetics enterprises, and life science, medical, and clinical research institutions. These services support drug target discovery, pharmacological efficacy and safety evaluation, disease molecular biomarker screening, tracing of pathogenic and drug-resistant bacteria, research on life development, and studies on the onset and progression of diseases.

Leveraging its multi-omics testing and innovative platforms, oebiotech closely monitors cutting-edge technological advancements, emphasizes the integration of industry, academia, and research, drives innovative R&D, and actively promotes the commercialization of technological achievements. Since 2018, oebiotech has gradually established a comprehensive R&D and production system for clinical molecular diagnostic kits through its wholly-owned subsidiary, Shanghai Jingzhun Biomedical Co., Ltd. To date, it has finalized the development of multiple Class III molecular diagnostic kits, with two products having sequentially entered clinical trials. These products are expected to receive regulatory approval and be launched on the market in 2022.

Oebiotech Group’s headquarters features 7,000 m² of office and laboratory space, including high-standard molecular biology and mass spectrometry laboratories, modern single-cell sequencing and spatial multi-omics laboratories, two academician expert workstations, and one professional R&D institution and technology center. Additionally, it has a 1,000 m² GMP-compliant production workshop and a 1,000 m² advanced R&D and quality control laboratory dedicated to the development and manufacturing of IVD products.

Regarding this round of financing,Wang Shuwei, Chairman of Oebiotech“The company stated: ‘We extend a warm welcome to our three new shareholders—Sinopharm Capital, Dongzheng Capital, and Dingshi Huize Capital—to oebiotech, and express our gratitude for their recognition of oebiotech’s mission and team. Leveraging the support from this round of financing, we will accelerate our efforts in the R&D of spatial multi-omics technologies, database construction, integrated multi-omics analysis, as well as the development and regulatory registration of molecular diagnostic products. Our goal is to establish oebiotech as a leading domestic brand in multi-omics services, thereby supporting scientific research and driving technological innovation. Furthermore, we are committed to building a comprehensive portfolio of reproductive genetics diagnostic products, contributing to eugenics and healthy births, and ultimately improving public health.’”

Zhou Xuan, Executive Director of Sinopharm CapitalIt stated: “With the continuous advancement of human life sciences, multi-omics technologies—including genomics, proteomics, transcriptomics, metabolomics, spatial omics, and single-cell sequencing—have provided robust support for life science research. Under the leadership of its core management team, chaired by Chairman Wang Shuwei and General Manager Xiao Yunping, Oebiotech has, over more than a decade of accumulation, built an outstanding team grounded in the core values of integrity, openness, pragmatism, and diligence, along with a comprehensive multi-omics technology platform, striving to become a respected biotechnology company. In addition to providing multi-omics services to the broader scientific research community, Oebiotech is continuously expanding its business boundaries. It has already launched multi-omics CRO (Contract Research Organization) services for industrial clients and, leveraging years of technical expertise, is gradually translating research products into clinical diagnostic offerings, thereby injecting new momentum into the company’s growth. We look forward to Oebiotech delivering enhanced services and products based on multi-omics technologies to research users, industrial clients, and clinical customers, thereby advancing the development of life sciences.”

Liu Xiaokang, Managing Director of Dongzheng Capital“The basic research sector of China’s life sciences industry is at the dawn of its takeoff. Through more than a decade of steadfast commitment and pioneering efforts, oebiotech has ascended step by step and is now poised for great heights. Led by Chairman Wang Shuwei and General Manager Xiao Yunping, the oebiotech team embodies integrity, openness, pragmatism, and drive. We are delighted to join hands with the team to support the long-term development of both basic scientific research and industry. We also look forward to the early market launch of oebiotech’s innovative reproductive genetics diagnostic product portfolio, which holds significant potential for clinical application, thereby contributing to eugenics and healthier births in China.”

Huang Chen, Vice President of Dingshi Huize CapitalIt stated: “In accordance with the central dogma of ‘gene–transcript–protein–metabolite,’ future life sciences research is trending from macroscopic to microscopic levels, from single-dimensional to multi-dimensional integrated studies, and from universal principles to in-depth applications in specific scenarios. As a leading multi-omics testing service platform in China, oebiotech boasts broad development prospects. We are highly optimistic about oebiotech’s management team, led by Chairman Wang Shuwei. This team not only brings extensive industry experience and profound insights but has also established a strong corporate culture, execution system, and professional workforce at oebiotech. While continuously enhancing the company’s scientific research service capabilities, they are steadily expanding into industrial client services and IVD molecular diagnostics, among other areas. We believe that oebiotech will continue to iterate and upgrade its technologies and products, steadily strengthen its core competitiveness, and drive the advancement of life sciences and precision medicine through multi-omics integrated research.”

Sinopharm Capital Management Co., Ltd. was established in 2012 as an equity investment institution focused on the healthcare sector, jointly initiated by Sinopharm Group and its management team. The firm currently manages assets under management exceeding RMB 6 billion. Its management team is structured according to market-oriented mechanisms, making it one of the earliest investment institutions in China dedicated to healthcare and wellness investments.

Shanghai Orient Securities Capital Investment Co., Ltd. (hereinafter referred to as “Orient Capital”) was established in February 2010. As a professional capital operation platform under Orient Securities, it is also a direct investment subsidiary of a securities company approved by the China Securities Regulatory Commission (CSRC). Orient Capital and the funds it manages have achieved cumulative asset investments of nearly RMB 30 billion. In the past two years, it has been honored with numerous awards, including Top 30 Best Chinese Private Equity Investment Institutions in China, Top 10 Best Private Fund Subsidiaries of Securities Companies in China, Top 100 Private Equity Investment Institutions in China (2020) by Zero2IPO, Top 10 Investment Institutions of Securities Companies in China, and the Annual Outstanding Institution for Equity Investment by Securities Companies at the 4th China Securities Journal Golden Bull Awards.

Dingshi Huize Capital is a professional investment firm specializing in the fields of biotechnology and life sciences. Adhering to the principles of long-term, value-based, and industry-chain investing, the company focuses on niche sectors such as biomedicine, human nutrition, and animal nutrition. It prioritizes investments in innovative biotechnologies, specialized R&D service platforms, functional products, and application solutions. Driven by in-depth research and comprehensive services, Dingshi Huize Capital strives to build an integrated investment ecosystem that fosters resource consolidation and industrial synergy.